期刊文献+

耐多药肺结核患者发现策略分析 被引量:4

Analysis of case finding strategy of multidrug-resistant pulmonary tuberculosis patients
下载PDF
导出
摘要 目的 探索并完善耐多药肺结核患者的发现策略.方法 根据不同的地理和经济条件选取天津、重庆万州、河南濮阳、浙江衢州、黑龙江大庆这5个地区作为研究地区.涂阳肺结核患者的标本天津、大庆和濮阳地区运输至地市级实验室进行痰培养和药物敏感性试验(简称“地市级同时完成培养及药敏试验模式”,模式1),衢州和重庆6县(区)则由县(区)级疾病预防控制中心(结核病防治所)实验室先进行痰培养,并将阳性培养物运输到地市级实验室进行药物敏感性试验(简称“县级培养地市级药敏试验模式”,模式2).从2010年3月到2012年2月,以5个研究地区痰涂片阳性患者7733例和天津市全部涂阴患者共3426例为主要筛查对象,进行结核分枝杆菌痰培养和异烟肼、利福平、链霉素、乙胺丁醇、氧氟沙星和卡那霉素的药敏试验,分析不同人群中耐多药及广泛耐药肺结核患者的检出率、送检及检出过程的时间间隔.并根据筛查结果使用SPSS 13.0统计学软件进行描述性统计分析和卡方检验,以P<0.05为差异有统计学意义.结果 模式1痰标本和模式2的菌株送检率分别为76.5%(3078/4026)和90.4%(2017/2232),差异有统计学意义(x^2=183.7,P<0.05);但培养阳性率模式1为89.9%(2455/2730)、模式2为87.2% (2232/2559),差异无统计学意义(x^2=0.2234,P>0.05).耐药确诊时间中位数(P25,P75)为104(86,138)d,个别甚至长达1年以上.复治涂阳、新涂阳和涂阴肺结核耐多药检出率分别为17.1%(129/755)、2.1%(97/4534)和0.5%(9/1937).结论 针对不同资源的地区可以采用县级培养模式或地市级培养模式.传统药敏试验时间长,有条件的地区宜早采用分子生物学快速检测技术.以涂阳患者为筛查对象可以发现大多数耐多药患者,资源丰富地区也可开展对涂阴患者的耐药检测. Objective To evaluate different case finding strategies of MDR TB,and to provide evidence for developing case finding strategy appropriately.Methods According to geographic and economic conditions,Tianjin,Wanzhou,Puyang,Quzhou and Daqing were selected as study areas.The sputum specimens of smear positive pulmonary tuberculosis(PTB) cases in Tianjin,Daqing and Puyang were sent to prefecture lab for culture and drug susceptibility test (DST) (Model 1),those in Quzhou and 6 counties (districts) were cultured in the lab at county level,and the positive cultural substance were sent to prefecture lab for DST (Model 2).7733 cases of smear posi tive PTB in 5 areas and all 3427 cases of smear negative patients in Tianjin registered from March 2010 to February 2013 were screened with sputum culture and DST (isoniazid,rifampicin,streptomycin,ethambutol,ofloxacin and kanamycin).Delay of diagnosis,MDRTB and XDR TB detection rate were collected and analysed by descriptive method and Chi square test by SPSS 13.0.Results Specimen examination rates of Model 1 and 2 were 76.5% (3078/4026)and 90.4% (2017/2232) respectively,and the difference had statistical significance (x^2 183.7,P〈0.05).The culture positive rate of Model 1 and 2 were 89.9% (2455/2730) and 87.2% (2232/2559) respectively,there was no statistical significance (x^2 0.2234,P〉0.05).The median of MDR diagnosis delay by traditional DST was 104(86,138) d,some even longer than 1 year.The detection rates from the highest to lowest were retreatment (17.1%,129/755),new smear positive (2.1%,97/4534) and smear negative (0.5%,9/1937).Conclusion Depending on the resources of different settings,either culture and DST by prefectural level model or culture by county level and DST by prefectural level model are reasonable.Because traditional DST takes longer period,rapid molecular test for drug resistance is recommended for developed setting.Selecting smear positive patient as the screning objects covers majority of MDR TB patients,screening MDR TB among smear negative is recommended for de veloped setting.
出处 《中国防痨杂志》 CAS 2014年第11期970-975,共6页 Chinese Journal of Antituberculosis
关键词 结核 抗药性 多种 细菌 微生物敏感性试验 Tuberculosis, pulmonary Drug resistance, multiple, bacterial Microbial sensitivity tests
  • 相关文献

参考文献13

  • 1赵雁林,姜广路.痰涂片镜检标准化操作及质量保证手册.北京:中国协和医科大学出版社,2009:4-9.
  • 2赵雁林,王黎霞,成诗明,等.分枝杆菌分离培养标准化操作程序及质量保证手册.北京:人民卫生出版社,2013:2.
  • 3赵雁林.王黎霞.结核分枝杆菌药物敏感性试验标准化操作程序及质量保证手册.北京:人民卫生出版社,2013.
  • 4王黎霞.中国结核病监控与评价指标.北京:中国协和医科大学出版社,2010.
  • 5谢兵.不同性状、不同保存条件痰标本结核菌培养阳性率比较[J].临床医学工程,2013,20(2):203-204. 被引量:5
  • 6宋红焕,孟尔旺,时金艳,彭红,许卫国.痰标本采集、储存及运输过程对培养结果影响的分析[J].中国防痨杂志,2011,33(6):372-376. 被引量:14
  • 7吕承菲,孙强,王黎霞,陈明亭,李仁忠,阮云洲,赵津,陈诚,苏伟.中国四个项目地区耐多药肺结核患者筛查率、检出率与发现及时性的比较[J].中国防痨杂志,2013,35(12):955-959. 被引量:13
  • 8World Health Organization.Prerequisites to country imple mentation of Xpert MTB/RIF and key action points at country level checklist.Geneva:World Health Organization,2011:1-4.
  • 9Trébucq A1,Anagonou S,Gninafon M,et al.Prevalence of primary and acquired resistance of Mycobacterium tuberculosis to antituberculosis drugs in Benin after 12 years of shor-course chemotherapy.Int J Tuber Lung,1999,3(6):466-470.
  • 10Pablos Méndez A,Raviglione MC,Laszlo A,et al.Global surveillance for antituberculosi-drug resistance,1994 1997.World Health Organization International Union against Tuberculosis and Lung Disease Working Group on Anti Tuberculosis Drug Resistance Surveillance.N Engl J Med,1998,338 (23):1641-1649.

二级参考文献27

  • 1宋凯.咳痰时间、痰标本性状与涂片抗酸杆菌检出关系分析[J].中国防痨杂志,2008,30(5):414-416. 被引量:17
  • 2肖东楼.中国结核病防治工作进展与成就[J].中国防痨杂志,2008,30(6):491-493. 被引量:34
  • 3李国刚,董彬,李俊娟,王峰,张建立,王丽芳,樊利红.运用不同实验方法提高菌阳肺结核患者检出率的实施性研究[J].河北医药,2009,31(21):2860-2861. 被引量:6
  • 4卫生部疾病预纺控制局,卫生部医政司,中国疾病预防控制中心.中国结核病防治规划实施工作指南[s].北京:中国协和医科大学出版社,2009:12—13.
  • 5Lumb R, Ardian M, Waramori G, Syahrial H, Tjitra E, Maguire GP, Anstey NM, Kelly PM. An alternative method for sputum storage and transport for mycoboxterium tuberculosis drug resistance surveys [J].Int J Tubere Lung Dis, 2006, 10 (2), 172-177.
  • 6中国防痨协会基础专业委员会.结核病诊断实验室检验规程[M].北京:中国教育出版社,2006.13-16.
  • 7Caramori G,Contoli M,Papi A.Treatment of bronchial asthma in adults.Current advances[J].Recenti Prog Med,2009,100(4):171-179.
  • 8Peters SP.Safety of inhaled corticosteroids in the treatment of persis tent asthma[J].J Natl Med Assoc,2006,98(6):851-861.
  • 9World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization, 2008.
  • 10Blower SM, Chou T. Modeling the emergence of the hot zones' :tuberculosis and the amplification dynamics of drug re sistance. Nat Med, 2004,10(10) : 1111-1116.

共引文献53

同被引文献47

  • 1中华人民共和国卫生部.全国结核病耐药性基线调查报告(2007-2008年)[M].北京:人民卫生出版社,2010:25-52.
  • 2World Health Organization.Global tuberculosis control[R]: WHO report. WHO/HTM/TB/2011. 16. Geneva:World Health Organization, 2011.
  • 3肖和平.耐多药结核病化学药物指南[M].北京:人民卫生出版社,2010:49-58.
  • 4赵雁林,王黎霞.结核分支杆菌药物敏感性试验标准化操作程序及质量保证手册[M].北京:人民卫生出版社,2013:15-20.
  • 5中国全球基金结核病项目办公室.第五轮中国全球基金结核病防治实施方案[M].北京:中国全球基金结核病项目办公室,2006.
  • 6Zhao Y, Xu S, Wang L, et al. National survey of drug-resistant tuberculosis in China[J]. N Engl J Med,2012,366 (23) :2161-2170.
  • 7WHO. Guidelines for the prograatic management of drugresistant tuberculosis ( Emergency Update 2008 ) [ R]. Geneva: WHO, 2008.
  • 8World Health Organization. Prerequises to country implementation of Xpert MTB/RIF and key action points at country level checklist[R]. Geneva:World Health Organization, 2011 : 1-4.
  • 9弭凤玲,王黎霞,李亮,李仁忠,张慧,姜世闻,王笑春,夏洋,陈明亭.中国全球基金耐多药结核病项目阶段性实施结果分析[J].中国防痨杂志,2010,32(11):700-704. 被引量:49
  • 10柳正卫,何海波,王晓萌,朱丽萍.浙江省第三次结核病耐药性监测结果分析[J].中华预防医学杂志,2011,45(2):171-173. 被引量:30

引证文献4

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部